Psychosis and relapse in bipolar disorder are related to GRM3, DAOA, and GRIN2B genotype

African Journal of Psychiatry (South Africa)

Volumn 13, Issue 4, 2010, Pages 297-301

  Dalvie, S ^a   Horn, N ^a   Nossek, C ^a   van der Merwe, L ^b,c   Stein, D ^a   Ramesar, R ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^c UNIVERSITY OF THE WESTERN CAPE   (South Africa)

Author keywords

G72 protein; Glutamate; GRIN2B receptor; Human; Manic depressive psychosis; Mglur3

Indexed keywords

DEXTRO AMINO ACID OXIDASE; DEXTRO AMINO ACID OXIDASE ACTIVATOR; METABOTROPIC RECEPTOR 3; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BIPOLAR DISORDER; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE FREQUENCY; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HETEROZYGOSITY; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MANIA; PATHOPHYSIOLOGY; PHENOTYPE; PILOT STUDY; PLESIOMORPHY; POLYMERASE CHAIN REACTION; POPULATION GENETICS; PSYCHOSIS; RELAPSE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 78049444461     PISSN: 19948220     EISSN: None     Source Type: Journal    
DOI: 10.4314/ajpsy.v13i4.61880     Document Type: Article

References (40)

1. Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RMA, Petukhova M, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch.Gen.Psychiatry 2007;64:543-552.
2. Pini S, de Queiroz V, Pagnin D, Pezawas L, Angst J, Cassano GB, et al. Prevalence and burden of bipolar disorders in European countries. European Neuropsychopharmacology 2005;15(4):425-434.
3. Müller-Oerlinghausen B, Berghöfer A, Bauer M. Bipolar disorder. The Lancet 2002;359(9302):241-247.
4. Murray CJL, Lopez AD. Global Burden of Disease: A Comprehensive Assessment of Mortality and Morbidity from Diseases, Injuries and Risk Factors in 1990 and Projected to 2020.: Harvard: World Health Organisation; 1996.
5. World Health Organisation. Chapter 2: Burden of Mental and Behavioural Disorders.; 2001.
6. American Psychiatric Association. Task Force on DSM-IV. DSM-IV: diagnostic and statistical manual of mental disorders.: American Psychiatric Association Washington, DC; 1994.
7. Carter C, Tasha D, Mundo E, Parikh SV, Kennedy JL. Early age at onset as a risk factor for poor outcome of bipolar disorder. J.Psychiatr.Res. 2003;37(4):297-303.
8. Perlis RH, Miyahara S, Marangell LB, Wisniewski SR, Ostacher M, DelBello MP, et al. Long-term implications of early onset in bipolar disorder: data from the first 1000 participants in the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol.Psychiatry 2004;55(9):875-881.
9. Green EK, Raybould R, Macgregor S, Hyde S, Young AH, O'Donovan MC, et al. Genetic variation of brain-derived neurotrophic factor (BDNF) in bipolar disorder: case-control study of over 3000 individuals from the UK. The British Journal of Psychiatry 2006;188(1):21.
10. Muller DJ, De L. Brain-derived neurotrophic factor (BDNF) gene and rapid-cycling bipolar disorder: family-based association study. The British Journal of Psychiatry 2006;189(4):317.
11. Vincze I, Perroud N, Buresi C, Baud P, Bellivier F, Etain B, et al. Association between brain-derived neurotrophic factor gene and a severe form of bipolar disorder, but no interaction with the serotonin transporter gene. Bipolar Disord. 2008;10(5):580-587.
12. Palomino A, González-Pinto A, Aldama A, González-Gómez C, Mosquera F, González-García G, et al. Decreased levels of plasma glutamate in patients with first-episode schizophrenia and bipolar disorder. Schizophr.Res. 2007;95(1-3):174-178.
13. Manji HK, Quiroz JA, Payne JL, Singh J, Lopes BP, Viegas JS, et al. The underlying neurobiology of bipolar disorder. World Psychiatry 2003;2(3):136.
14. Karkanias NB, Papke RL. Subtype-specific effects of lithium on glutamate receptor function. J.Neurophysiol. 1999;81(4):1506-1512.
15. Paddock S, Laje G, Charney D, Rush AJ, Wilson AF, Sorant AJM, et al. Association of GRIK4 with outcome of antidepressant treatment in the STAR* D cohort. Am.J.Psychiatry 2007;164(8):1181.
16. Fallin MD, Lasseter VK, Avramopoulos D, Nicodemus KK, Wolyniec PS, McGrath JA, et al. Bipolar I disorder and schizophrenia: a 440-singlenucleotide polymorphism screen of 64 candidate genes among Ashkenazi Jewish case-parent trios. The American Journal of Human Genetics 2005;77(6):918-936.
17. Lyon L, Kew JNC, Corti C, Harrison PJ, Burnet PWJ. Altered hippocampal expression of glutamate receptors and transporters in GRM2 and GRM3 knockout mice. Synapse 2008;62(11).
18. Choudary P, Molnar M, Evans S, Tomita H, Li J, Vawter M, et al. Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proceedings of the National Academy of Sciences 2005;102(43):15653-15658.
19. Crespi B, Summers K, Dorus S. Adaptive evolution of genes underlying schizophrenia. Proceedings of the Royal Society B: Biological Sciences 2007;274(1627):2801-2810.
20. Egan MF, Straub RE, Goldberg TE, Yakub I, Callicott JH, Hariri AR, et al. Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proceedings of the National Academy of Sciences 2004;101(34):12604-12609.
21. Tang YP, Wang H, Feng R, Kyin M, Tsien J. Differential effects of enrichment on learning and memory function in NR2B transgenic mice. Neuropharmacology 2001;41(6):779-790.
22. Martucci L, Wong AHC, De Luca V, Likhodi O, Wong GWH, King N, et al. N-methyl-d-aspartate receptor NR2B subunit gene GRIN2B in schizophrenia and bipolar disorder: Polymorphisms and mRNA levels. Schizophr.Res. 2006;84(2-3):214-221.
23. Avramopoulos D, Lasseter VK, Fallin MD, Wolyniec PS, McGrath JA, Nestadt G, et al. Stage II follow-up on a linkage scan for bipolar disorder in the Ashkenazim provides suggestive evidence for chromosome 12p and the GRIN2B gene. Genetics in Medicine 2007;9(11):745.
24. Miyatake R, Furukawa A, Suwaki H. Identification of a novel variant of the human NR2B gene promoter region and its possible association with schizophrenia. Mol.Psychiatry 2002;7:1101-1106.
25. Chumakov I, Blumenfeld M, Guerassimenko O, Cavarec L, Palicio M, Abderrahim H, et al. Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. Proceedings of the National Academy of Sciences 2002;99(21):13675-13680.
26. Hashimoto K, Engberg G, Shimizu E, Nordin C, Lindström LH, Iyo M. Reduced D-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients. Progress in Neuropsychopharmacology & Biological Psychiatry 2005;29(5):767-769.
27. Hattori E, Liu C, Badner JA, Bonner TI, Christian SL, Maheshwari M, et al. Polymorphisms at the G72/G30 gene locus, on 13q33, are associated with bipolar disorder in two independent pedigree series. The American Journal of Human Genetics 2003;72(5):1131-1140.
28. Chen Y, Akula N, Detera-Wadleigh S, Schulze T, Thomas J, Potash J, et al. Findings in an independent sample support an association between bipolar affective disorder and the G72/G30 locus on chromosome 13q33. Mol.Psychiatry 2004;9(1):87-92.
29. Addington AM, Gornick M, Sporn AL, Gogtay N, Greenstein D, Lenane M, et al. Polymorphisms in the 13q33. 2 gene G72/G30 are associated with childhood-onset schizophrenia and psychosis not otherwise specified. Biol.Psychiatry 2004;55(10):976-980.
30. Korostishevsky M, Kaganovich M, Cholostoy A, Ashkenazi M, Ratner Y, Dahary D, et al. Is the G72/G30 locus associated with schizophrenia? Single nucleotide polymorphisms, haplotypes, and gene expression analysis. Biol.Psychiatry 2004;56(3):169-176.
31. Schumacher J, Jamra RA, Freudenberg J, Becker T, Ohlraun S, Otte A, et al. Examination of G72 and D-amino-acid oxidase as genetic risk factors for schizophrenia and bipolar affective disorder. Mol.Psychiatry 2004;9(2):203-207.
32. Wang X, He G, Gu N, Yang J, Tang J, Chen Q, et al. Association of G72/G30 with schizophrenia in the Chinese population. Biochem.Biophys.Res.Commun. 2004;319(4):1281-1286.
33. Le-Niculescu H, Patel S, Bhat M, Kuczenski R, Faraone S, Tsuang M, et al. Convergent functional genomics of genome-wide association data for bipolar disorder: Comprehensive identification of candidate genes, pathways and mechanisms. 2008.
34. Norton N, Williams HJ, Dwyer S, Ivanov D, Preece AC, Gerrish A, et al. No evidence for association between polymorphisms in GRM3 and schizophrenia. BMC Psychiatry 2005 May 13;5:23.
35. Tochigi M, Suga M, Ohashi J, Otowa T, Yamasue H, Kasai K, et al. No association between the metabotropic glutamate receptor type 3 gene (GRM3) and schizophrenia in a Japanese population. Schizophr.Res. 2006;88(1-3):260-264.
36. Diller KC, Gilbert WA, Kocher TD. Selective sweeps in the human genome: A starting point for identifying genetic differences between modern humans and chimpanzees. Mol.Biol.Evol. 2002;19(12):2342-2345.
37. Kraepelin E. Über Sprachstörungen im Traume.: Verlag von Wilhelm Engelmann; 1906.
38. Carter C. Multiple genes and factors associated with bipolar disorder converge on growth factor and stress activated kinase pathways controlling translation initiation: implications for oligodendrocyte viability. Neurochem.Int. 2007;50(3):461-490.
39. Vara JÁF, Casado E, de Castro J, Cejas P, Belda-Iniesta C, González-Barón M. PI3K/Akt signalling pathway and cancer. Cancer Treat.Rev. 2004;30(2):193-204.
40. Rahman SN, Stratton M. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007;447(7145):661-678.